# CJC-1295 Ipamorelin: A Nightfall Reading of the GHRH-and-GHRP Record > CJC-1295 Ipamorelin pairs a long-acting GHRH analogue with a selective ghrelin-receptor agonist to raise the sleeping growth-hormone pulse. Cited single-component research, honestly framed. A nightfall reading of the GHRH-and-GHRP record: the long hold, the single sharp pulse, the slow-wave sleep it is said to deepen — every quantitative claim cited, and the untested-blend caveat kept in plain sight. ## The gist, before the dark CJC-1295 Ipamorelin is two research peptides used together, not one drug. CJC-1295 is a long-acting version of a natural signal called GHRH (the hormone that tells the body to make growth hormone). Ipamorelin copies a second natural signal, ghrelin, and nudges the same gland a different way. Pushed together they raise growth hormone (GH) — the body's overnight repair and growth signal — more than either does alone. People use the pair hoping for deeper sleep, faster recovery, and a slow shift toward leaner shape. Studies of each peptide on its own back parts of that story; the *fixed pairing itself has never been tested in a controlled human trial*. Neither one is FDA-approved. There are downsides too — puffiness, hunger, a head-rush after a shot — and real cautions for some people. What people report, the good and the bad, is laid out on [the effects page](/effects). ## What the CJC-1295 and ipamorelin literature has shown A single subcutaneous dose of CJC-1295 with DAC raised mean plasma GH 2- to 10-fold for six days or more, and IGF-1 (the liver-made growth factor that carries most of GH's downstream signal) 1.5- to 3-fold for nine to eleven days, in healthy adults; across repeat dosing IGF-1 stayed above baseline as long as 28 days [1]. Ipamorelin earned its title as the first *selective* growth hormone secretagogue — at doses more than 200 times the amount needed to release GH, it left ACTH and cortisol untouched, while matching GHRP-6's GH output in swine [2]. That the two reach for GH along separate roads is the whole point of the pairing. In normal men, submaximal doses of a GHRP combined with GHRH released GH synergistically — more than the sum of the parts — the two arms acting through independent mechanisms [3]. At the receptor level, co-activating the cloned ghrelin and GHRH receptors produced roughly twice the cAMP signal of GHRH alone [4]. These are single-component and related-peptide findings; read the full [CJC-1295 Ipamorelin research](/research) for how they are stitched together — and where they stop. ## The pairing: a long hold and a single pulse The teal arm is CJC-1295. It is engineered to last. A Drug Affinity Complex (DAC) — a small chemical handle on the peptide — latches covalently onto albumin, a carrier protein in the blood, dragging the molecule's half-life out to several days [5]. Stripped of that handle, the no-DAC form, **Mod GRF (1-29)**, fades in roughly half an hour. One molecule holds the door open for days; the other knocks once and is gone. The distinction matters, and the [dosage research](/dosage) keeps the two apart. The violet arm is ipamorelin: a five-amino-acid pentapeptide, `Aib-His-D-2-Nal-D-Phe-Lys-NH2`, that taps the ghrelin receptor and triggers a clean, sharp GH burst. Where older releasing peptides also stirred hunger hormones and stress hormones, ipamorelin was bred for quiet — GH, and little else [2]. The two together are the [growth hormone secretagogue](/growth-hormone-secretagogue) idea in its tidiest form. ## The sleep lens Most of GH's nightly tide arrives in deep sleep, and the ghrelin arm has a documented hand in that depth. Intravenous ghrelin boluses — four 50-µg pulses, an hour apart — increased slow-wave sleep and delta-wave activity in healthy men, tying ghrelin-receptor signalling to sleep architecture itself [8]. A 2025 study went further, mapping a neuroendocrine circuit that gates GH release on sleep, refining how the two are wired together [9]. This is the lens this reading is dealt: the nocturnal GH pulse, the slow-wave depth, the aurora that arrives only after dark. ## What the studies do not say The honesty is the spine of this site. There is no peer-reviewed human pharmacology study of the pre-mixed CJC-1295/ipamorelin combination; every claim about *the blend* is inferred from each compound's separate literature plus the general GHRH-plus-GHRP synergy work, which used related peptides, not this exact pair. Neither peptide is approved for any human use, and both sit on the WADA prohibited list at all times under Section S2 (peptide hormones and growth factors). The class is generally well tolerated in the short term, but the standing safety concern is mild glucose elevation from reduced insulin sensitivity, and the long-term oncologic questions are open, not answered [6]. None of that is a verdict against the molecules — it is the shape of what is, and is not, yet known. The body-composition and recovery claims live in the [CJC-1295 Ipamorelin effects](/effects) page, clearly marked as what is studied versus what is merely reported. --- A nightfall reading of the CJC-1295 and ipamorelin literature — the aurora is wonder, the steel is rigor, and nothing here is a clinic, a prescription, or a thing for sale.